Anti-Histone H3 (citrulline R2) antibody [EPR17703]
- 20ul selling size
- RabMAb
- Advanced Validation
- Recombinant
- 각 태그의 뜻
5
(1 리뷰)
|
(17 제품이 사용된 논문 )
- IP
Supplier Data
Immunoprecipitation - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (AB176843)
Histone H3 was immunoprecipitated from 0.35 mg HEK-293T (human embryonic kidney) transfected with PADI4 expression vector containing a GFP-tag treated with 10 mM calcium chloride and 10 µM lonomycin for 4 hours, whole cell lysate 10 ug with ab176843 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab176843 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(ab131366) was used at 1/5000 dilution. Lane 1 : HEK-293T (human embryonic kidney) transfected with PADI4 expression vector containing a GFP-tag treated with 10 mM calcium chloride and 10 µM lonomycin for 4 hours, whole cell lysate 10 ug
Lane 2 : ab176843 IP in HEK-293T transfected with PADI4 expression vector containing a GFP-tag treated with 10 mM calcium chloride and 10 µM lonomycin for 4 hours whole cell lysate
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab176843 in HEK-293T transfected with PADI4 expression vector containing a GFP-tag treated with 10 mM calcium chloride and 10 µM lonomycin for 4 hours whole cell lysate
Blocking and dilution buffer and concentration : 5% NFDM/TBST.
Exposure time : 3 min
All lanes:
Immunoprecipitation - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (ab176843)
Predicted band size: 15 kDa
false
- I-ELISA
Supplier Data
Indirect ELISA - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (AB176843)
ELISA analysis of Human Histone H3 (ci recombinant protein at 100 ng/ml with ab176843. An Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) at 1/2500 dilution was used as the secondary antibody.
- WB
Supplier Data
Western blot - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (AB176843)
Blocking/Dilution buffer : 5% NFDM/TBST.
PADI4 catalyzes the citrullination of arginine residues of histone proteins.
All lanes:
Western blot - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (ab176843) at 1/500 dilution
Lane 1:
MCF7 (Human breast adenocarcinoma cell line) cells transfected with vector control
Lane 2:
MCF7 (Human breast adenocarcinoma cell line) cells transfected with PADI4
Secondary
All lanes:
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 15 kDa
Observed band size: 15 kDa
false
Exposure time: 30s
- WB
Supplier Data
Western blot - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (AB176843)
Blocking/Dilution buffer : 5% NFDM/TBST.
PADI4 catalyzes the citrullination of arginine residues of histone proteins.
All lanes:
Western blot - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (ab176843) at 1/500 dilution
Lane 1:
NIH/3T3 (Mouse embyro fibroblast cells) cells transfected with vector control
Lane 2:
NIH/3T3 (Mouse embyro fibroblast cells) cells transfected with PADI4
Secondary
All lanes:
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 15 kDa
Observed band size: 15 kDa
false
Exposure time: 30s
- PepArr
Unknown
Peptide Array - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (AB176843)
ab176843 was tested in Peptide Array against 501 different modified and unmodified histone peptides; each peptide is printed on the array at six concentrations (each in triplicate).
Circle area represents affinity between the antibody and a peptide : all antigen-containing peptides are displayed as red circles, all other peptides as blue circles. The affinity is calculated as area under curve when antibody binding values are plotted against the corresponding peptide concentration. Each circle area is normalized to the peptide with the strongest affinity.
The complete dataset, including full list of all peptides and information on the position of each peptide in the diagram, is available under the Product Protocol section.
- WB
CiteAb
Western blot - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (AB176843)
Histone H3 (citrulline R2) western blot using anti-Histone H3 (citrulline R2) antibody [EPR17703] ab176843. Publication image and figure legend from Zhou, Y., Chen, B., et al., 2017, Front Immunol, PubMed 28993780.
ab176843 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab176843 please see the product overview.
Citrullination of extracellular substrates by intact neutrophils or neutrophil-conditioned media. (A) Upper panel, anti-citrullinated fibrinogen immunoblot of the supernatant from the incubation of fibrinogen for the indicated times in the presence of human neutrophils (lanes 1–7). Lane 7, fibrinogen was omitted. Lane 8 only contained fibrinogen. Lane 9, fibrinogen and recombinant PAD4. Lane 10, neutrophil-conditioned media. Lane 11, neutrophil with 2 mM EGTA. Lower panel, Coomassie Brilliant blue staining as a loading control. The bands corresponding to the α, β, and γ chains of fibrinogen are indicated. Note that α-fibrinogen is rapidly degraded by neutrophil-associated proteases. (B) Control immunoblot with anti-GAPDH, an intracellular protein, to demonstrate that significant lysis of neutrophils occurs only after 4 h of incubation with Triton X at 37°C under the experimental conditions. (C) Upper panel, anti-citrullinated histone H3 immunoblot of the supernatant from the incubation of histone H3 for the indicated time periods in the presence of human neutrophils (lanes 1–7). Lane 7, histone was omitted. Lane 8 only contained histone H3. Lane 9 contained histone H3 and recombinant PAD4. Lane 10, neutrophil-conditioned media. Lane 11, neutrophil with 2 mM EGTA. Note that citrullinated histone H3 is also cleaved by neutrophil-associated protease(s) to generate a slightly smaller protein. Lower panel, anti-histone H3 immunoblot as a loading control. This antibody does not recognize the proteolytically cleaved H3. (D) A similar experiment performed in the presence of an MMP inhibitor, a protease inhibitor cocktail, or both, as indicated. Lower panel, Coomassie Brilliant blue staining as a loading control. All data are representative of five independent experiments with different donors.
false
관련 conjugated 항체와 다양한 조성의 항체 (1)
-
Anti-Histone H3 (citrulline R2) antibody [EPR17703] - BSA and Azide free
Reactivity 정보
제품 세부 정보
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
특성 및 보관 정보
제형
Purification 테크닉
보관 버퍼
배송 시 보관 조건
적절한 단기 보관 기간
적절한 단기 보관 조건
적절한 장기 보관 조건
분주 정보
보관 정보
제품 프로토콜
- Visit the General protocols
- Visit the Troubleshooting
- Download peptideArrayWebsite|en
Chemical treatment is required for detection of endogenous citrullinated proteins in cell lines. PADs (including PADI2 and PADI4) are the enzymes that hydrolyze arginine to citrulline, in the presence of Ca2+ and ionomycin. Please refer to PMID: 26360112
Controls:
- Mock (no transfection)
- Transfection reagent–only control
- Empty vector control
- Vehicle control for chemical treatment
Generation of PADI2 or PADI4 overexpression cell line and treatment with CaCl2/Ionomycin:
1. Prior to transfection with PADI2 or PADI4 expression vector, seed cells in complete medium and place in a 37°C, 5% CO2 incubator for 24 hours or until cells reach 70-80% confluence.
For a single T-175 flask we recommend seeding the following common cell lines as follows in 30 mL media:
- HEK-293T: 1x107 cells
- MCF7: 2.5-4x106 cells
- NIH3T3: 4-5x106 cells
2. Once cells have reached confluence, prepare the PADI2 or PADI4 expression vector for transfection using your preferred method (PMID: 33976969).
3. 24-48 hours after transfection, remove the medium from the cells and replace with fresh complete medium containing 10 mM CaCl2 (ab285384) and 10 uM Ionomycin (ab120116) and incubate for 2-4 hours.
Key Considerations:
For alternative cell lines, you should confirm the transfectability, growth rate, and sensitivity of the cell line to the planned chemical treatment. Incubation times and treatment length may need to be adjusted.
Western Blot Conditions:
Recommended SDS-PAGE Gel Type: 4-20% Tris-glycine
Recommended Running Buffer: Tris-Glycine-SDS
Primary: 1/500 dilution at 4°C overnight or room temperature for 1 hour
Blocking: 5% NFDM at room temperature for 1 hour
Positive Control: Cell line overexpressing PADI4 and treated with CaCl2/Ionomycin
Negative Control: Cell line overexpressing PADI4
Additional resources:
Lysate preparation protocol
Lysate preparation protocol - nuclear proteins
Lysate preparation protocol - low molecular weight proteins
Western blot troubleshooting
타겟 정보
대체 명칭 보기
제품이 사용된 논문 (17)
Recent publications for all applications. Explore the 전체 목록and refine your search
Nature communications 16:5393 PubMed40562767
2025
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 15:9746 PubMed39528459
2024
Applications
Unspecified application
Species
Unspecified reactive species
Nature structural & molecular biology 31:977-995 PubMed38321148
2024
Applications
Unspecified application
Species
Unspecified reactive species
Philosophical transactions of the Royal Society of London. Series B, Biological sciences 378:20220248 PubMed37778388
2023
Applications
Unspecified application
Species
Unspecified reactive species
Molecular biology and evolution 39: PubMed34730808
2021
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in immunology 12:716250 PubMed34737738
2021
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in immunology 12:675315 PubMed34616390
2021
Applications
Unspecified application
Species
Unspecified reactive species
Nature immunology 22:1107-1117 PubMed34385713
2021
Applications
Unspecified application
Species
Unspecified reactive species
Cell 184:3915-3935.e21 PubMed34174187
2021
Applications
Unspecified application
Species
Unspecified reactive species
Journal of thrombosis and haemostasis : JTH 18:2732-2743 PubMed32654410
2020
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com